10x Genomics, Inc. (TXG)
| Market Cap | 10.66B +638.0% |
| Revenue (ttm) | 616.91M -4.3% |
| Net Income | -75.13M |
| EPS | -0.59 |
| Shares Out | 130.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,750,604 |
| Open | 78.60 |
| Previous Close | 77.28 |
| Day's Range | 78.52 - 85.12 |
| 52-Week Range | 11.16 - 102.81 |
| Beta | 1.99 |
| Analysts | Buy |
| Price Target | 69.47 (-15.07%) |
| Est. Earnings | Nov 5, 2026 |
About TXG
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium p... [Read more]
Financial Performance
In 2025, 10x Genomics's revenue was $642.82 million, an increase of 5.25% compared to the previous year's $610.79 million. Losses were -$43.54 million, -76.16% less than in 2024.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for TXG stock is "Buy." The 12-month stock price target is $69.47, which is a decrease of -15.07% from the latest price.
News
10x Genomics price target raised to $80 from $50 at BofA
BofA raised the firm’s price target on 10x Genomics (TXG) to $80 from $50 and keeps a Neutral rating on the shares. The life science tools sector has further re-rated…
10x Genomics announces research collaboration with Fred Hutchinson
10x Genomics (TXG) announced a multi-project research collaboration with Fred Hutchinson Cancer Center, one of the nation’s leading cancer research institutions, to advance the use of single cell and ...
10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers
Multi-project collaboration with Fred Hutch Cancer Center spans biomarker discovery in bladder cancer and a single cell approach to residual disease detection in acute myeloid leukemia PLEASANTON, Cal...
10x Genomics price target raised to $110 from $52 at Barclays
Barclays raised the firm’s price target on 10x Genomics (TXG) to $110 from $52 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science…
10x Genomics falls -13.4%
10x Genomics (TXG) is down -13.4%, or -$13.07 to $84.67.
10x Genomics announces first commercial shipments of Atera
10x Genomics (TXG) announced the first commercial shipments of Atera, marking a major milestone for a platform that will redefine what’s possible in spatial biology. Introduced in April of this…
10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times from hours to minutes, putting rapid, iterative analysis at the fingertips of every researcher PLEA...
10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands
Extraordinary early global demand, ambitious new research programs and an expansive technology roadmap mark the beginning of a new era for biological understanding PLEASANTON, Calif., Sept. 29, 2026 /...
10x Genomics price target raised to $90 from $40 at Leerink
Leerink raised the firm’s price target on 10x Genomics (TXG) to $90 from $40 and keeps a Market Perform rating on the shares. The firm stays on the sidelines given…
10x Genomics initiated with a Buy at Argus
Argus initiated coverage of 10x Genomics (TXG) with a Buy rating and $110 price target The firm sees accelerating demand for the company’s newly launched Atera spatial biology platform, the…
10x Genomics price target raised to $80 from $47 at Piper Sandler
Piper Sandler raised the firm’s price target on 10x Genomics (TXG) to $80 from $47 and keeps a Neutral rating on the shares. Pharma and biotech spend roughly $300B annually…
10x Genomics partners with Korea-based Lunit for AI-enabled pathology analysis
10x Genomics (TXG) will incorporate Lunit’s AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow. Lunit SCOPE IO will be used to analyze Hematoxylin and Eosin ...
Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research
10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery SEOUL, Sou...
10x Genomics assumed with a Neutral at UBS
UBS analyst Doug Schenkel assumed coverage of 10x Genomics (TXG) with a Neutral rating and $68 price target The firm initiated and resumed 25 life science and diagnostics tools companies.
10x Genomics initiated with a Sector Perform at RBC Capital
RBC Capital initiated coverage of 10x Genomics (TXG) with a Sector Perform rating and $70 price target The firm has a constructive view on the Atera launch and spatial opportunity.
10x Genomics reports patent infringement win against Parse Biosciences
10x Genomics (TXG) announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (QGEN), willfully infringed three…
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life sc...
10x Genomics price target raised to $65 from $50 at Stephens
Stephens analyst Mason Carrico raised the firm’s price target on 10x Genomics (TXG) to $65 from $50 and keeps an Overweight rating on the shares. The firm is updating its…
10x Genomics price target raised to $60 from $50 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on 10x Genomics (TXG) to $60 from $50 and keeps a Buy rating on the shares. The firm met with management…
10x Genomics price target raised to $47 from $42 at Piper Sandler
Piper Sandler raised the firm’s price target on 10x Genomics (TXG) to $47 from $42 and keeps a Neutral rating on the shares following quarterly results. The firm cites updated…
10x Genomics price target raised to $40 from $37 at Morgan Stanley
Morgan Stanley raised the firm’s price target on 10x Genomics (TXG) to $40 from $37 and keeps an Equal Weight rating on the shares.
10x Genomics Earnings Call Transcript: Q2 2026
Q2 revenue grew 3% YoY (excluding settlements), driven by strong consumables growth and exceptional demand for the new Atera platform, though instrument sales declined. Full-year guidance was raised, with Atera orders exceeding shipment capacity and AI adoption fueling demand across customer segments.
10x Genomics Earnings release: Q2 2026
10x Genomics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
10x Genomics Quarterly report: Q2 2026
10x Genomics has published its Q2 2026 quarterly earnings report on August 6, 2026.